Singer Capital Markets is delighted to have been appointed as Broker to Sareum Holdings plc with immediate effect.
Sareum is a clinical-stage small molecule company actively involved in developing next generation kinase inhibitors to treat autoimmune diseases and cancer.
Ticker: SAR
Market Cap: £19.3 million*
Website: Click here
*As at 30th October 2025
Account Team
| Investment Banking | |||
|---|---|---|---|
 Phil Davies Managing Director, Investment Banking
|
 Patrick Weaver Analyst, Investment Banking |
||
| Research & Sales | |||
|---|---|---|---|
 Karl Keegan Head of Research |
Edward Sham Research Analyst |
Jonathan Dighe Equity Sales |
|
| Investor Relations | |||
|---|---|---|---|
 Kitty McArdle Investor Relations |
|||
Let’s Talk
If you’re looking for more information about any of our services, or if you can’t find what you’re looking for directly on our site, please do not hesitate to contact us.
